Hasanain Kamil OWADH, Rana A. GHALEB, Fatima Adnan ALZUBAIDI

Forty Micromole Hydroxychloroquine Enhanced Cytotoxic Effect of Doxorubicin Against Laryngeal Cancer Cell Line HEp-2

Autophagy processes are essential biological mechanisms control human cell survival and induction of cell death. Many researches indicate that cancer cells growth is affected by inhibition or induction of autophagy processes and laryngeal cancer "the most common type of head and neck cancer" is one of various types of tumors which effected by autophagy process. Numerous articles studied impact of adding autophagy inhibiter to cancer treatment protocol, and the current work study the in-vitro anticancer effect of doxorubicin alone and in combination with an autophagy inhibitor agent hydroxychloroquine against HEp-2 (laryngeal cancer) cell line. The present study suggested valuable effect of doxorubicin anticancer activity against HEp-2 cell line when used after hydroxychloroquine pretreatment, which may play promising role in treatment of laryngeal cancer.

PDF

___

[1] Elshazly, E, Zhang S, Yu L, Zhang Y, Ke L, Gong R. Hydroxychloroquine enhances anticancer effect of DOX/folate-phytosterol-carboxymethyl cellulose nanoparticles in A549 lung cancer cells. Trop J Pharm Res. 2020; 19 (2): 219-225. [CrossRef]
[2] Elicin O, Giger R. Comparison of current surgical and non-surgical treatment strategies for early and locally advanced stage glottic laryngeal cancer and their outcome. Cancers (Basel) 2020; 12 (3): 732. [CrossRef]
[3] Singh H, Chauhan A. Primary small cell carcinoma of the larynx: Report of a rare tumor. Case Rep Oncol Med. 2011; 2011: Article ID 978676. [CrossRef]
[4] Ali MQ, Raji A, Abdulameer MS. Patterns of laryngeal cancer presentation of Iraqi patients. Rev Latinoam Hipertens. 2021: 16(4): 298-303. [CrossRef] [5] Steffen C, Piwonski I, Heiland M, Stromberger C, Kofla G, Doll C, Coordes A, Beck-Broichsitter B. Influence of tumor site on survival in young patients with head and neck squamous cell carcinoma. Curr Oncol. 2022; 29(2): 969-980.[CrossRef]
[6] Christowitz C, Davis T, Isaacs A, Niekerk G, Hattingh S, Engelbrecht A. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer 2019; 19(1): 757. [CrosssRef]
[7] Taymaz-Nikerel H, Karabekmez M, Eraslan S, Kırdar B. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Reports 2018: 8(1): 13672. [CrossRef]
[8] Marinello J, Delcuratolo M, Capranico G. Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci. 2018; 19(11): 3480. [CrossRef]
[9] Luis C, Castaño-Guerrero Y, Soares R, Sales G, Fernandes R. Avoiding the interference of doxorubicin with MTT measurements on the MCF-7 breast cancer cell line. Methods Protoc. 2019; 2(2): 29. [CrossRef]
[10] Mohanty S, Aghighi M, Yerneni K, Theruvath JL, Daldrup‐Link HE. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’signals off and ‘eat me’signals on. Mol Oncol. 2019;13(10):2049-2061. [11] Owadh HKH, Mohammad BI, Al-Muhana SJ, Obied HN, Ghaleb RA, Najah R. The synergistic effect of resveratrol and hydroxychloroquine on osteosarcoma cell line (MG-63) by autophagy modulating. Lat Am J Pharm, 2020; 39(8): 1671-1676.
[12] Barbeau L, Keulers T, Rouschop K. Tumors Responsive to autophagy-ınhibition ıdentification and biomarkers. Cancers. 2020; 12: 2463. [CrossRef] [13] Alvarez-Meythaler JG, Garcia-Mayea Y, Mir C, Kondoh H, LLeonart ME. Autophagy takes center stage as a possible cancer hallmark. Front Oncol. 2020; 2178. [CrossRef]
[14] Garcia-Mayea Y, Mir C, Muñoz L, Benavente S, Castellvi J, Temprana J, Maggio V, Lorente J, Paciucc R, Lleonart M. Autophagy inhibition as a promising therapeutic target for laryngeal cancer. Carcinogenesis 2019; 1–10. [CrossRef][
[15] Bradford R, Ferlito A, Devaney K, Mäkitie A, Rinaldo A. Prognostic factors in laryngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2020; 5: 74–81. [CrossRef]
[16] Owadh H, Mohammad B, Al-Muhana S, Obied H, Ghaleb R, Hadi N. The autophagy inhibitor hydroxychloroquine enhances sensitivity of osteosarcoma cell line mg-63 to doxorubicin treatment. Sys Rev Pharm. 2020; 11(5): 63-69. [CrossRef]
[17] Shippey E, Wagler V, Collamer A. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018; 85(6): 459-467. [CrossRef] [18] Halcrow PW, Geiger JD, Chen X. Overcoming chemoresistance: Altering pH of cellular compartments by chloroquine and hydroxychloroquine. Front Cell Dev Biol. 2021; 9: 170. [CrossRef]
[19] Ashrafizadeh, M, Zarrabi A, Hashemi F, Zabolian A, Saleki A, Bagherian M, Azami N, Bejandi A, Hushmandi K, Li Ang H, Makvandi P, Khan H, Kumar A. Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: Enhancing antitumor activity. Pharmaceut. 2020; 12: 1084. [CrossRef]
[20] Khalili‐Tanha G, Moghbeli M. Long non‐coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cell Mol Biol Lett. 2021; 26: 39. [CrossRef].
[21] Małek, A, Taciak B, Sobczak K, Grzelak A, Wójcik M, Mieczkowski J, Lechowski R, Zabielska-Koczywa˛SK. Enhanced cytotoxic effect of doxorubicin conjugated to glutathione-stabilized gold nanoparticles in canine osteosarcoma—in vitro studies. Molecules 2021; 26: 3487. [CrossRef].
22- Li, Y, Cao F, Li M, Li P, Yu Y, Xiang L, Xu T, Lei J, Tai Y, Zhu J, Yang B, Jiang Y, Zhang X, Duo L, Chen P, Yu X. Hydroxychloroquine induced lung cancer suppression by enhancing chemosensitization and promoting the transition of M2-TAMs to M1-like macrophages. J Exp Clin Cancer Res. 2018; 37: 259. [CrossRef].